217 related articles for article (PubMed ID: 28270164)
1. Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Cranston A; Stocken DD; Stamp E; Roblin D; Hamlin J; Langtry J; Plummer R; Ashworth A; Burn J; Rajan N
Trials; 2017 Mar; 18(1):111. PubMed ID: 28270164
[TBL] [Abstract][Full Text] [Related]
2. Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
Danilenko M; Stamp E; Stocken DD; Husain A; Zangarini M; Cranston A; Stones R; Sinclair N; Hodgson K; Bowett SA; Roblin D; Traversa S; Plummer R; Veal G; Langtry JAA; Ashworth A; Burn J; Rajan N
JAMA Dermatol; 2018 Aug; 154(8):913-921. PubMed ID: 29955768
[TBL] [Abstract][Full Text] [Related]
3. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
4. Phenotype variability in tumor disorders of the skin appendages associated with mutations in the CYLD gene.
Parren LJMT; Giehl K; van Geel M; Frank J
Arch Dermatol Res; 2018 Sep; 310(7):599-606. PubMed ID: 29974194
[TBL] [Abstract][Full Text] [Related]
5. Clinical, genetic and experimental studies of the Brooke-Spiegler (CYLD) skin tumor syndrome.
Andersson MK; Kölby L; Nilsson JA; Stenman G
J Plast Surg Hand Surg; 2019 Apr; 53(2):71-75. PubMed ID: 30676842
[TBL] [Abstract][Full Text] [Related]
6. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells.
Rajan N; Andersson MK; Sinclair N; Fehr A; Hodgson K; Lord CJ; Kazakov DV; Vanecek T; Ashworth A; Stenman G
J Pathol; 2016 Jun; 239(2):197-205. PubMed ID: 26969893
[TBL] [Abstract][Full Text] [Related]
8. Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.
Rajan N; Elliott R; Clewes O; Mackay A; Reis-Filho JS; Burn J; Langtry J; Sieber-Blum M; Lord CJ; Ashworth A
Oncogene; 2011 Oct; 30(41):4243-60. PubMed ID: 21552290
[TBL] [Abstract][Full Text] [Related]
9. Inherited pulmonary cylindromas: extending the phenotype of CYLD mutation carriers.
Brown SM; Arefi M; Stones R; Loo PS; Barnard S; Bloxham C; Stefanos N; Langtry JAA; Worthy S; Calonje E; Husain A; Rajan N
Br J Dermatol; 2018 Sep; 179(3):662-668. PubMed ID: 29569226
[TBL] [Abstract][Full Text] [Related]
10. A case of multiple familial trichoepitheliomas responding to treatment with the Hedgehog signaling pathway inhibitor vismodegib.
Baur V; Papadopoulos T; Kazakov DV; Agaimy A; Hartmann A; Isbary G; Wirtz RM; Schultz ES
Virchows Arch; 2018 Aug; 473(2):241-246. PubMed ID: 29934657
[TBL] [Abstract][Full Text] [Related]
11. Novel and recurrent germline and somatic mutations in a cohort of 67 patients from 48 families with Brooke-Spiegler syndrome including the phenotypic variant of multiple familial trichoepitheliomas and correlation with the histopathologic findings in 379 biopsy specimens.
Grossmann P; Vanecek T; Steiner P; Kacerovska D; Spagnolo DV; Cribier B; Rose C; Vazmitel M; Carlson JA; Emberger M; Martinek P; Pearce RL; Pearn J; Michal M; Kazakov DV
Am J Dermatopathol; 2013 Feb; 35(1):34-44. PubMed ID: 23249834
[TBL] [Abstract][Full Text] [Related]
12. Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction.
Rajan N; Langtry JA; Ashworth A; Roberts C; Chapman P; Burn J; Trainer AH
Arch Dermatol; 2009 Nov; 145(11):1277-84. PubMed ID: 19917957
[TBL] [Abstract][Full Text] [Related]
13. Large germline deletions of the CYLD gene in patients with Brooke-Spiegler syndrome and multiple familial trichoepithelioma.
Vanecek T; Halbhuber Z; Kacerovska D; Martinek P; Sedivcova M; Carr RA; Slouka D; Michal M; Kazakov DV
Am J Dermatopathol; 2014 Nov; 36(11):868-74. PubMed ID: 25347032
[TBL] [Abstract][Full Text] [Related]
14. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
15. Mild phenotype of familial cylindromatosis associated with an R758X nonsense mutation in the CYLD tumour suppressor gene.
Oiso N; Mizuno N; Fukai K; Nakagawa K; Ishii M
Br J Dermatol; 2004 Nov; 151(5):1084-6. PubMed ID: 15541090
[TBL] [Abstract][Full Text] [Related]
16. A novel large deletion of the CYLD gene causes CYLD cutaneous syndrome in a Chinese family.
Zhu R; Xu J; Shen J; Li W; Tan F; Li C; Wei Z; Liu Y; Bai Y
Mol Genet Genomic Med; 2020 Oct; 8(10):e1441. PubMed ID: 32783365
[TBL] [Abstract][Full Text] [Related]
17. Diverse presentations of cutaneous mosaicism occur in CYLD cutaneous syndrome and may result in parent-to-child transmission.
Arefi M; Wilson V; Muthiah S; Zwolinski S; Bajwa D; Brennan P; Blasdale K; Bourn D; Burn J; Santibanez-Koref M; Rajan N
J Am Acad Dermatol; 2019 Dec; 81(6):1300-1307. PubMed ID: 31085270
[TBL] [Abstract][Full Text] [Related]
18. Multiple (familial) trichoepitheliomas: a clinicopathological and molecular biological study, including CYLD and PTCH gene analysis, of a series of 16 patients.
Kazakov DV; Vanecek T; Zelger B; Carlson JA; Spagnolo DV; Schaller J; Nemcova J; Kacerovska D; Vazmitel M; Sangüeza M; Emberger M; Belousova I; Fernandez-Figueras MT; Kempf W; Meyer DR; Rütten A; Baltaci M; Michal M
Am J Dermatopathol; 2011 May; 33(3):251-65. PubMed ID: 21389835
[TBL] [Abstract][Full Text] [Related]
19. Squamous Cell Carcinoma and Multiple Familial Trichoepitheliomas: A Recurrent Association.
Dubois A; Mestre T; Oliphant T; Husain A; Rajan N
Acta Derm Venereol; 2018 Oct; 98(9):910-911. PubMed ID: 29972217
[No Abstract] [Full Text] [Related]
20. Diverse assays from a single skin punch biopsy to assess topical drug intervention.
Danilenko M; Hodgson K; Stones R; Husain A; Zangarini M; Veal G; Rajan N
Br J Dermatol; 2019 Apr; 180(4):937-938. PubMed ID: 30367471
[No Abstract] [Full Text] [Related]
[Next] [New Search]
